BiotechBreakthroughs

$KZIA Prediction: $5 million purchase of GDC-0084 asset from Genentech will ultimately go down as the most brilliant transaction in the history of cancer treatment.

William Blair calling "Bullshit" tonite and downgrading $INKT to Market Perform Old recirculated one patient data Looks like HC W will get the offering on Monday for keeping quiet earlier in the day

$INKT Bleeding lower after hours as sellers try to escape before the probable HCW cap raise hits the wires tonight/early next week. Target $10.

$INKT BUYER BEWARE. HCW currently working stock in preparation for a PIPE likely in the $10-15 range. Chasers at current levels going to lose 3/4 of their investment imminently.

$INKT OLD NEWS -- From May 15 press release: "A peer-reviewed publication expected in the first half of 2025 will detail a complete remission in a patient with metastatic testicular cancer treated in MiNK’s Phase 1 trial with a single infusion of agenT-797."

$INKT CAUTION: Today's news is NOT NEW, previously reported in a press release on May 15. Company will use this unwarranted surge in shares to raise funds at steep discount.

$KZIA URGENT BREAKING NEWS: $CMRX JUST ACQUIRED FOR $935 MILLION. Kazia market cap just over $4 million here. ***KAZIA LEAD DRUG IS USED IN COMBINATION THERAPY WITH CMRX LEAD DRUG*** As close to a no-brainer STRONG BUY RIGHT NOW in biotech as you get. pmc.ncbi.nlm.nih.gov/articles/PMC10…

$DWTX "Dogwood is Dogshit: Fair Value = 75 cents." Promoter Pump is over.. dump in progress. Don't get caught holding the bag.

$KZIA $CMRX Dordaviprone works best in combination with Kazia's pax, so expect FDA to greenlight. As soon as traders connect the dots, Kazia shares will be re-rated much, much higher.

Incredibly proud to share the latest work from #DunLab, published in #CancerResearch! We highlight the combination of ONC201 and paxalisib for the treatment of DMG, the preclinical data informing PNOC022. Follow this tweetorial for a summary: (1/10) aacrjournals.org/cancerres/arti…

$KZIA $CMRX Kazia meets with FDA this month to discuss AA. Given current market capitalization, similar PR will launch shares to $20+ instantly.

$KZIA $CMRX Kazia meets with FDA this month to discuss AA. Given current market capitalizaiton, s$similar PR will launch shares to $20+ instantly.

$KZIA a Strong Buy on the $CMRX move. cancer.gov/research/parti… pubmed.ncbi.nlm.nih.gov/37195023/

$KZIA Clueless low volume sellers in this biotech/healthcare "RFK panic" may wish to consider that GBM took the life of his uncle.

$KZIA Kazia Therapeutics schedules Type C meeting with FDA to discuss potential next steps for Paxalisib in treating newly diagnosed Glioblastoma Multiforme. More Info: pryzm.ozmosi.com/product/14290 $XBI $IBB $XPH $PPH

$VCNX up 50%, $MNPR down 40% since this post a week ago.

$VCNX Tiny biotech trading under cash foreshadowing PROMISING ALZHEIMER'S DATA in exactly one week. BUY $VCNX, SELL $MNPR is the prudent trade.

$VCNX Risk-reward here is EXPONENTIALLY more favorable than buying $MNPR. Monopar simply paying for the right to use a drug (really shouldn't even be trading up on this). Expecting a much more significant partnership announcement for Vaccinex. $VCNX current mkt cap 1/10 of $MNPR.

$VCNX Shares trade under cash, majority of float owned by insiders. CEO has purchased millions of shares. $MNPR

$VCNX MAJOR PARTNERSHIP ANNOUNCEMENT implied in recent PR ... the same news that ignited $MNPR

$VCNX VACCINEX TO REPORT PROMISING NEW EFFICACY DATA AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE one week from today. $VCNX the next $MNPR?